Literature DB >> 10968704

Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.

B R DeYoung1, M R Wick.   

Abstract

Pathologists are now asked frequently to determine the primary site for metastatic carcinomas of unknown origin (MCUO), using adjunctive morphological techniques such as electron microscopy, immunohistology, and other modalities. The authors present an algorithmic immunohistochemical approach to this problem that is based on their experience with over 2,800 routinely-processed epithelial malignancies of various types. These have been studied with antibodies to keratins, vimentin, epithelial membrane antigen, MOC-31, tumor associated-glycoprotein-72 (recognized by monoclonal antibody B72.3), prostate-specific antigen, thyroglobulin, gross cystic disease fluid protein-15, carcinoembryonic antigen, CA-125, CA19-9, placental alkaline phosphatase, S100 protein, and estrogen receptor protein. The algorithm that is structured around these 14 analytes is based on the relative predictive value of each marker, which in turn, determines its place in the sequence of interpretation. The authors' experience with this approach shows 67% accuracy with regard to the ultimately determined site of origin for MCUO, a figure which is similar to that reported by other investigators.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968704

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  21 in total

1.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Authors:  P Argani; C R Antonescu; P B Illei; M Y Lui; C F Timmons; R Newbury; V E Reuter; A J Garvin; A R Perez-Atayde; J A Fletcher; J B Beckwith; J A Bridge; M Ladanyi
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

3.  A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin.

Authors:  Dimitri Talantov; Jonathan Baden; Tim Jatkoe; Kristina Hahn; Jack Yu; Yashoda Rajpurohit; Yiqiu Jiang; Chang Choi; Jeffrey S Ross; David Atkins; Yixin Wang; Abhijit Mazumder
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

4.  Evaluation of a gene expression microarray-based assay to determine tissue type of origin on a diverse set of 49 malignancies.

Authors:  Andrew H Beck; Juan Rodriguez-Paris; James Zehnder; Iris Schrijver
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

Review 5.  Carcinomas of an unknown primary origin--diagnosis and treatment.

Authors:  Christophe Massard; Yohann Loriot; Karim Fizazi
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

Review 6.  Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Authors:  John D Hainsworth; F Anthony Greco
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 7.  [The role of pathology in the diagnostics of CUP syndrome].

Authors:  A Stenzinger; M Kriegsmann; W Weichert
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

8.  The diagnostic value of image guided percutaneous fine needle aspiration biopsy in equivocal mediastinal masses.

Authors:  Mine G Güllüoğlu; Zeki Kiliçaslan; Alper Toker; Göksel Kalayci; Dilek Yilmazbayhan
Journal:  Langenbecks Arch Surg       Date:  2006-03-14       Impact factor: 3.445

Review 9.  Molecular classification of cancers of unknown primary site.

Authors:  F Anthony Greco; Mark G Erlander
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

10.  [Pathohistology and molecular genetic diagnostics in CUP syndrome].

Authors:  C Wittekind; L-C Horn
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.